COVID-19 INVESTOR UPDATE

CSL LIMITED

9 April, 2020

Paul Perreault, CEO
Andrew Cuthbertson, Chief Scientific Officer
David Lamont, CFO
Paul McKenzie, Chief Operating Officer
Forward looking statements
The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. CSL Group is also involved in multiple litigations in the ordinary course of business. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks
Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

After struggling for years to get an accurate diagnosis, hereditary angioedema (HAE) patient Kathrin Schoen is working to ensure the next generation of patients doesn’t have to wait so long.
COVID-19
Overview

• Primary objective is to ensure safety and wellbeing of our staff, donors and continuity of supply of medicines to patients

• Expertise, technologies, equipment and materials are being provided to support the response to COVID-19

• Providing additional southern hemisphere influenza vaccine doses to Australia

• Business continuity plans implemented at all sites
COVID-19
Employees

• Health and welfare of staff are of primary importance to CSL
• Wherever possible, staff are strongly encouraged to work remotely
• Facilities are ‘critical infrastructure/essential facilities’ and excluded from most government shutdown processes
• On-boarding of critical staff positions accelerated
• International and domestic travel limited to business critical
Plasma Collections

Challenge

- Plasma collections expected to be impacted

Mitigation

- Collection centres designated ‘essential critical infrastructure’
- ‘Safe passage’ letters provided to staff, donors and key vendors
- FDA initiatives to release plasma earlier in the cycle
- Potential to accelerate plasma collections post crisis
- New donors expected to arise following economic downturn
- Long manufacturing cycle. Today’s collections underpin sales next fiscal year

Protecting Staff and Donors

Actions

- Pre-assessment of potential donors
- Re-direction of donors to sister centers if needed
- Plasma designed social distancing
- Enhanced cleaning & disinfectant procedures

Challenge

- Plasma collections expected to be impacted

Mitigation

- Collection centres designated ‘essential critical infrastructure’
- ‘Safe passage’ letters provided to staff, donors and key vendors
- FDA initiatives to release plasma earlier in the cycle
- Potential to accelerate plasma collections post crisis
- New donors expected to arise following economic downturn
- Long manufacturing cycle. Today’s collections underpin sales next fiscal year

Protection Staff and Donors

Actions

- Pre-assessment of potential donors
- Re-direction of donors to sister centers if needed
- Plasma designed social distancing
- Enhanced cleaning & disinfectant procedures
COVID-19
Plasma Collection Centres
COVID-19
Commercial

• Products are life saving or life extending, usually non-discretionary
• Demand is consistent with plan:
  • Requests for IVIG elevated
  • Strong demand for influenza vaccines
• Currently no ‘stock-outs’ – no interruption to the supply chain
• Alternative delivery mechanisms utilised as needed
• China:
  • Wuhan facility operations recommenced
  • Additional efforts to continue import supply of albumin (ie. air instead of sea freight)
Core R&D Capabilities

- Globally integrated R&D network
- World class expertise in immunological science, vaccinology and protein therapeutics
- Extensive Hyperimmune product development and manufacturing capabilities
- Scaled recombinant protein-based vaccine development and manufacturing
- Recombinant protein rMAb therapeutics development and manufacturing
- MF59 proprietary adjuvant technology and manufacturing
## Focused COVID-19 Response

<table>
<thead>
<tr>
<th>Population</th>
<th>Prevention</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>General public</td>
<td>At-risk healthcare workers and infected patients</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Therapeutic Options</th>
<th>Prevention</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Vaccines</td>
<td>* Hyperimmunes Polyclonal antibodies</td>
<td>* Monoclonal antibodies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CSL Assets &amp; Capabilities</th>
<th>Prevention</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant technology</td>
<td>Process development</td>
<td>CSL312; CSL324 IL6; C1inhibitor</td>
</tr>
<tr>
<td>Scaled manufacturing</td>
<td>Scaled manufacturing</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Collaborators</th>
<th>Prevention</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Queensland/CEPI</td>
<td>Hyperimmune: Alliance with Takeda and others</td>
<td>Academic clinical researchers</td>
</tr>
<tr>
<td></td>
<td>Polyclonal: Sab Therapeutics</td>
<td></td>
</tr>
</tbody>
</table>

* CSL platform
COVID-19
Summary

• Plasma collections presents a challenge
  • Various initiatives expected to mitigate impact

• Actively pursuing COVID-19 response consistent with core R&D and manufacturing capabilities

• Modest delays expected in capital projects and clinical trials
  • Potential to accelerate activity post crisis to ensure no material change to original plan

• Strong capital position
  • Est. ~$1.1bn available liquidity

• Profit guidance for FY20 reaffirmed
  • ~$2,110m to $2,170m @CC²,³

¹ For forward looking statements, refer to Legal Notice on page 2
² Constant Currency (CC) removes the impact of exchange rates movements to facilitate comparability.
³ Full year FX impact expected to be $100 million unfavourable assuming exchange rates remain steady for the remainder of the financial year
CSL Limited
Contact

Bernard Ronchi
Senior Manager Investor Relations
✦ +61 3 9389 3470
✉ Bernard.Ronchi@csl.com.au

Mark Dehring
VP Investor Relations
✦ +61 3 9389 3407
✉ mark.dehring@csl.com.au